PROSTATE CANCER: Cabazitaxel—a key therapeutic option in prostate cancer

    loading  Checking for direct PDF access through Ovid

Abstract

Treatment with cabazitaxel is associated with improved survival in patients with metastatic castration-resistant prostate cancer. Bahlet al.recently reported that patient-reported quality-of-life metrics were stable—with a trend towards improvements with increasing numbers of treatment cycles—in 112 patients treated with cabazitaxel in the UK.

Related Topics

    loading  Loading Related Articles